These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Mehta N; Wayne AS; Kim YH; Hale GA; Alvarado CS; Myskowski P; Jaffe ES; Busam KJ; Pulitzer M; Zwerner J; Horwitz S Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):20-5. PubMed ID: 22001256 [TBL] [Abstract][Full Text] [Related]
17. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma. Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904 [TBL] [Abstract][Full Text] [Related]
19. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. Heald P; Mehlmauer M; Martin AG; Crowley CA; Yocum RC; Reich SD; J Am Acad Dermatol; 2003 Nov; 49(5):801-15. PubMed ID: 14576658 [TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas. Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]